Shuttle Pharmaceuticals Holdings, Inc. Annual Report: A Year in Review

This guide explains how Shuttle Pharmaceuticals performed this past year. The company has shifted its business model significantly, and it is important to understand what that means for your investment.

1. The Big Pivot: From Drugs to AI

The biggest news is that Shuttle Pharmaceuticals has changed its business model. They bought Molecule.ai for about $10 million in stock, moving away from traditional drug development. They have officially ended clinical trials for their lead cancer drug, Ropidoxuridine, which was once the core of their value.

They now position themselves as an "AI-driven technology company." Their platform uses AI to help researchers predict how molecules behave, find promising drug candidates, and automate research. They aim to be the "foundational AI layer" for pharmaceutical research. However, this is a crowded field. They face competition from tech giants like NVIDIA and Google, as well as specialized firms like Schrodinger and Recursion Pharmaceuticals. These competitors have much larger research budgets and established customers.

2. Financial Health: A Constant Race

The company is spending heavily and currently earns no revenue. Their financial situation is very fragile:

• The Cash Crunch: They ended 2025 with only $0.3 million in cash, down from $1.9 million the year before. At their current spending rate, they have less than one month of cash left.
• Rising Costs: Running the business is getting more expensive. Total operating expenses rose to $11.7 million in 2025, up from $9.8 million in 2024.
• The "Going Concern" Risk: Auditors have flagged "substantial doubt" about the company’s ability to stay in business. They noted that the company does not have enough cash to operate for the next twelve months. Shuttle needs immediate, ongoing funding to avoid running out of money.
• Accounting Complexity: The company uses complex financial tools like "convertible notes" and "warrants." These allow them to borrow money or raise cash that can later be turned into stock. Because these are recorded as liabilities that change in value based on stock price, they cause wild swings in reported profit. This often hides the reality of their actual cash flow.

3. The Cost of Survival: Dilution and Reverse Splits

To stay afloat, the company has taken drastic steps that directly impact your investment:

• Massive Dilution: They have repeatedly sold new shares and warrants to raise cash. This means more shares are issued, reducing your ownership percentage. To keep their stock price above the $1.00 Nasdaq minimum, they performed a 1-for-25 reverse stock split in June 2025, following a 1-for-8 split in 2024. If you owned 200 shares before 2024, you would now hold only one.
• The 2026 Offering: In March 2026, they raised another $3.36 million by selling more stock and warrants. This further reduced the value of existing shares and added potential pressure on the stock price.

4. The Bottom Line

Shuttle Pharmaceuticals is a high-risk bet on AI software. They have abandoned their previous research and rely on constant, expensive fundraising just to stay listed. You are funding a startup that spends over $11 million a year with zero revenue.

While they are building sophisticated tools, they have yet to prove that pharmaceutical partners will pay for them. Given their lack of revenue, deep cash shortages, and history of issuing more shares to survive, this is a high-stakes situation. The risk of losing your entire investment is significant.

Investor Takeaway: Before considering an investment, weigh the company's transition to AI against its severe liquidity issues and history of shareholder dilution. The company's survival depends entirely on its ability to secure continuous external funding, as it currently generates no revenue to cover its operating costs.